Exploring the Need for More Comprehensive Biomarker Testing in Early-Stage NSCLC

EP. 1: Introduction to Biomarker Testing in NSCLC

ByCarrie Lee, MD, MPH,David Harpole, MD ,Gerard Silvestri, MD ,Eric Vail, MD

December 23rd 2025

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and education are vital for improvement.

EP. 2: Key Takeaways on Biomarker Utilization in Metastatic NSCLC

ByCarrie Lee, MD, MPH,David Harpole, MD ,Gerard Silvestri, MD ,Eric Vail, MD

December 23rd 2025

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for reflexive testing and improved communication.

EP. 3: Examining Biomarker Testing in Early-stage NSCLC

ByCarrie Lee, MD, MPH,David Harpole, MD ,Gerard Silvestri, MD ,Eric Vail, MD

January 7th 2026

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved testing strategies and healthcare access.

EP. 4: Patient Case #1: Newly Diagnosed Stage 3A NSCLC

ByCarrie Lee, MD, MPH,David Harpole, MD ,Gerard Silvestri, MD ,Eric Vail, MD

January 7th 2026

A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance of multidisciplinary evaluation.

EP. 5: Patient Case #2: Newly Diagnosed Stage 3B NSCLC

ByCarrie Lee, MD, MPH,David Harpole, MD ,Gerard Silvestri, MD ,Eric Vail, MD

January 14th 2026

This case examines effective management of early-stage non–small cell lung cancer (NSCLC) requiring integrating imaging, laboratory results, and molecular profiling to guide therapy.

EP. 6: Remaining Unmet Needs in Biomarker Testing in Early-Stage NSCLC

ByCarrie Lee, MD, MPH,David Harpole, MD ,Gerard Silvestri, MD ,Eric Vail, MD

January 14th 2026

This segment examines optimal care for patients with early-stage non–small cell lung cancer (NSCLC) relying on coordinated multidisciplinary collaboration.